Bioatla Inc (BCAB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.89M
Last updated: Nov 13, 2026 at 4:00 PM ET
Bioatla Inc (BCAB) Financials: Revenue, Profit and Cash Flow
Bioatla reported revenue of $2.00M for the fiscal year ended Dec 31, 2025, down 81.8% from the year before. That year, net income was -$59.61M with a net margin of -2980.3%, operating cash flow was -$48.20M and free cash flow was -$48.20M. The quarter ended Sep 30, 2026 had revenue of $250.00K and net income of -$7.90M.
Revenue and Margins
Over the 7 years to Dec 2025, revenue fell from $10.63M, a compound annual decline of 21.2%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $2.00M | -81.8% | 100.0% | -2965.3% | -2980.3% |
| Dec 2024 | $11.00M | N/A | 100.0% | -672.2% | -634.3% |
| Dec 2023 | $0 | N/A | N/A | N/A | N/A |
| Dec 2022 | $0 | -100.0% | N/A | N/A | N/A |
| Dec 2021 | $250.00K | -41.7% | 100.0% | -38576.0% | -38160.8% |
| Dec 2020 | $429.00K | -91.8% | 100.0% | -7016.1% | -8357.3% |
| Dec 2019 | $5.20M | -51.1% | 100.0% | -543.6% | -574.1% |
| Dec 2018 | $10.63M | N/A | -147.5% | -265.7% | -272.7% |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.00M | $11.00M | $0 | $0 | $250.00K | $429.00K | $5.20M | $10.63M |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $26.30M |
| Gross profit | $2.00M | $11.00M | $0 | $0 | $250.00K | $429.00K | $5.20M | -$15.68M |
| Research and development | $43.57M | $63.09M | $103.73M | $79.35M | $58.27M | $19.93M | $25.92M | $26.30M |
| Operating income | -$59.30M | -$73.94M | -$129.69M | -$108.14M | -$96.44M | -$30.10M | -$28.27M | -$28.23M |
| Net income | -$59.61M | -$69.78M | -$123.46M | -$106.48M | -$95.40M | -$35.85M | -$29.86M | -$28.98M |
| EBITDA | N/A | -$72.22M | -$128.55M | -$106.93M | -$95.11M | N/A | N/A | -$27.24M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $250.00K | $6.50M | $0 | $2.00M | $0 | $0 | $0 | $0 | $11.00M | $0 | $0 | $1.71M |
| Gross profit | $250.00K | $6.50M | $0 | $2.00M | $0 | $0 | $0 | -$11.65M | $11.00M | $0 | $0 | -$368.00K |
| Operating income | -$8.36M | $227.00K | -$9.31M | -$9.26M | -$13.79M | -$18.65M | -$17.61M | -$16.24M | -$11.27M | -$21.97M | -$24.46M | -$28.54M |
| Net income | -$7.90M | $452.00K | -$6.34M | -$9.78M | -$15.78M | -$18.71M | -$15.33M | -$14.88M | -$10.59M | -$21.07M | -$23.23M | -$26.93M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $1.43M by $5.69M. Shareholder equity was negative, at -$36.19M, as total liabilities of $50.02M exceeded total assets of $13.83M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $13.83M | $52.42M | $119.66M | $225.74M | $254.42M | $244.94M | $9.34M | $16.64M |
| Current assets | $8.01M | $51.23M | $116.41M | $220.43M | $247.29M | $240.68M | $4.51M | $12.66M |
| Cash and equivalents | $7.12M | $49.05M | $111.47M | $215.51M | $244.98M | $238.60M | $3.70M | $10.86M |
| Total liabilities | $50.02M | $38.16M | $48.99M | $45.40M | $43.60M | $34.96M | $65.35M | $45.08M |
| Short-term debt | $1.43M | $836.00K | $1.62M | $1.52M | $1.39M | $682.00K | $9.71M | N/A |
| Long-term debt | N/A | N/A | N/A | $0 | N/A | $682.00K | $8.41M | $15.00M |
| Shareholder equity | -$36.19M | $14.27M | $70.67M | $180.34M | $210.82M | $209.97M | -$55.96M | -$28.46M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.11M | $9.51M | $8.57M | $13.83M | $15.91M | $27.13M | $38.29M | $52.42M | $62.24M | $68.64M | $89.20M | $119.66M |
| Total liabilities | $44.70M | $45.74M | $45.88M | $50.02M | $47.15M | $43.87M | $37.74M | $38.16M | $39.27M | $37.27M | $39.48M | $48.99M |
| Cash and equivalents | $576.00K | $1.54M | $1.96M | $7.12M | $8.32M | $18.21M | $32.36M | $49.05M | $56.52M | $61.66M | $80.63M | $111.47M |
| Shareholder equity | -$43.60M | -$36.24M | -$37.31M | -$36.19M | -$31.24M | -$16.75M | $547.00K | $14.27M | $22.97M | $31.37M | $49.72M | $70.67M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$48.20M | -$71.94M | -$104.02M | -$90.42M | -$62.21M | -$36.33M | -$9.64M | -$35.32M |
| Capital expenditures | $0 | $0 | $98.00K | $268.00K | $924.00K | $590.00K | $1.51M | $988.00K |
| Free cash flow | -$48.20M | -$71.94M | -$104.11M | -$90.69M | -$63.14M | -$36.92M | -$11.15M | -$36.30M |
| Dividends paid | N/A | N/A | N/A | N/A | $0 | $19.00K | $5.00K | N/A |
| Investing cash flow | $0 | $0 | -$98.00K | -$265.00K | -$924.00K | -$590.00K | -$1.51M | -$988.00K |
| Financing cash flow | $6.28M | $9.51M | $77.00K | $61.21M | $69.51M | $271.82M | $4.00M | $5.02M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$967.00K | -$419.00K | -$5.27M | -$7.92M | -$9.88M | -$14.12M | -$16.29M | -$16.78M | -$5.13M | -$19.19M | -$30.83M | -$29.92M |
| Capital expenditures | N/A | N/A | $0 | $0 | $0 | $14.20M | $0 | $0 | $0 | $0 | $0 | $8.00K |
| Free cash flow | N/A | N/A | -$5.27M | -$7.92M | -$9.88M | -$28.32M | -$16.29M | -$16.78M | -$5.13M | -$19.19M | -$30.83M | -$29.93M |
Frequently Asked Questions About BCAB
What is Bioatla's annual revenue?
Bioatla reported revenue of $2.00M for the fiscal year ended Dec 31, 2025.
How fast is Bioatla's revenue growing?
Revenue was down 81.8% for the fiscal year ended Dec 31, 2025 compared with the year before.
Is Bioatla profitable?
No. Bioatla reported net income of -$59.61M for the fiscal year ended Dec 31, 2025, with a net margin of -2980.3%.
How much free cash flow does BCAB generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$48.20M minus capital expenditures of $0 produced free cash flow of -$48.20M.
How much debt does Bioatla have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $1.43M and cash and equivalents of $7.12M.
BCAB pages: Overview, Earnings, Financials, Competitors